MDxHealth Announces Presentations on the ConfirmMDx(TM) for Prostate Cancer Test at the ASCO Genitourinary Cancers Symposium

MDxHealth Announces Presentations on the ConfirmMDx(TM) for Prostate Cancer 
Test at the ASCO Genitourinary Cancers Symposium 2013 
IRVINE, CA and LIEGE, BELGIUM -- (Marketwire) -- 02/13/13 -- 
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic
company that develops and commercializes epigenetic tests to support
the diagnosis and treatment of cancer patients, today announced that
the company will present results from two important studies involving
its ConfirmMDx(TM) for Prostate Cancer test at the ASCO Genitourinary
Cancers Symposium 2013, February 14-16, Orlando, Florida, USA.  
Following are details for each embargoed session (all times are in
Eastern Standard Time) follow: 
Thursday, February 14, 2013 
Abstract Title: Epigenetic Field Effects for DNA Methylation Markers
Extend Over Multiple Histologically Benign Prostate Biopsy Cores 
Lead Author: Sandra M Gaston PhD, New England Baptist Hospital,
Harvard Medical School
 Location: Prostate Cancer poster session:
Poster 116
 Time: 11:45AM  
Abstract Title: Multi-gene Epigenetic MSP Assay Predicts Risk for
Prostate Cancer in Histopathologically Negative Biopsies
Author: Leander van Neste PhD, MDxHealth SA, Liege, Belgium 
Location: Prostate Cancer poster session: Poster 95
 Time: 11:45AM 
About ConfirmMDx for Prostate Cancer
 Over 650,000 American men
receive a negative prostate biopsy result each year; though
approximately 25% of these men may still harbor occult prostate
cancer. This well-documented risk of undetected cancer, often with
clinically significant Gleason scores, leads to a high rate of repeat
biopsies with over 40% of men receiving at least one repeat biopsy,
and many receiving a 3rd and 4th biopsy. Today's gold standard
diagnostic approach is the prostate biopsy procedure, collecting
10-12 needle core biopsy samples, however this sampling represents
less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is
an epigenetic assay to help urologists distinguish patients who have
a true-negative biopsy from those at risk for occult cancer. The test
is able to detect an epigenetic field effect or "halo" associated
with the cancerization process at the DNA level in cells adjacent to
cancer foci. This molecular "halo" around a cancer lesion can be
present despite having a normal appearance under the microscope. The
test helps urologists rule out prostate cancer-free men from
undergoing unnecessary repeat biopsies and helps rule in high-risk
patients who may require repeat biopsies and potential treatment. 
About MDxHealth
 MDxHealth is a molecular diagnostics company that
develops and commercializes advanced epigenetic tests for cancer
assessment and the personalized treatment of patients. The company's
first commercial product, the ConfirmMDx for Prostate Cancer test,
has been shown to help distinguish patients who have a true-negative
biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary
platform and a strong epigenetic product pipeline focused on the
development of products for brain and lung cancers. The company is
based in Irvine, California with a European headquarters in Liege,
Belgium. For more information visit MDxHealth website at 
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of MDxHealth and
the market in which it operates. Such statements and estimates are
based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the company's control, and may
turn out to be materially different. MDxHealth expressly disclaims
any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based unless required by law or regulation. This
press release does not constitute an offer or invitation for the sale
or purchase of securities or assets of MDxHealth in any jurisdiction.
No securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as
amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws. 
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are
trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective
Dr Jan Groen, CEO 
US: +1 949 812 6979 
BE: +32 4 364 20 70  
Mike Sinclair 
Halsin Partners 
UK: +44 20 7318 2955 
Cell: +44 7968 022075  
Seth Lewis 
The Trout Group 
US: +1 646 378 2952
Press spacebar to pause and continue. Press esc to stop.